H1N1 pandemic "vastly overrated" by WHO
The handling of the H1N1 pandemic by the World Health Organization (WHO), EU agencies and national governments led to a "waste of large sums of public money, and unjustified scares and fears about the health risks faced by the European public", according to a report released by the Council of Europe.
The handling of the H1N1 pandemic by the World Health Organization (WHO), EU agencies and national governments led to a “waste of large sums of public money, and unjustified scares and fears about the health risks faced by the European public”, according to a
“This is a pandemic that never really was,” said Flynn, when presenting the report to the Social, Health and Family Affairs Committee of the Parliamentary Assembly of the Council of Europe.
The report is another blow to the WHO, which has been subject to a number of reviews and inquiries following its handling of the pandemic, which was
One of Flynn’s particular concerns regarding the handling of the pandemic was the lack of transparency of the WHO’s decision-making processes and the possible influence of the pharmaceutical industry on some key decisions. This issue that has also been raised by a
“The existence of these conflicts of interest is of grave concern, more so because the WHO has not been transparent about them,” said Fiona Godlee, Editor in Chief of the BMJ, in a
The BMJ/The Bureau report concludes that the current system is “struggling to manage the inherent conflict between the pharmaceutical industry, WHO, and the global public health system”, and stresses that although planning for the worst is a sensible approach, there are “damaging issues” that must be addressed.”
Both reports believe that there should be greater transparency and better governance in public health, and both highlight the importance of rebuilding public confidence in health decisions taken by the WHO and European and national authorities. Flynn’s report includes a number of recommendations, including the “urgent” need for a thorough review of decisions taken by public health authorities during the H1N1 pandemic.
Godlee also believes that the decisions made during the pandemic must be evaluated “with full disclosure of the evidence behind the decisions, the names of those contributing to the decisions, and their conflicts of interest”.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

